A Scalable Generative AI Pipeline for Early-Stage Neuro-Biomarker Profiling in Alzheimer's Pathogenesis
DOI:
https://doi.org/10.5281/zenodo.20444811Keywords:
Generative Artificial Intelligence, Data Engineering Pipelines, Predictive Biomarker Discovery, Alzheimer’s Disease Analytics, Kidney Disease Analytics, MultiOmics Data Integration, Clinical Data Harmonization, Reproducible Research Pipelines, Scalable Biomedical Architectures, Metadata Standardization, Data Quality Control, Synthetic Data Generation, Feature Representation Learning, Explainable Biomarker Models, Translational Bioinformatics, CloudNative Data Infrastructure, Model Validation Frameworks, EvidenceBased Discovery, Precision Medicine Enablement, Lifecycle Oriented Data Engineering.Abstract
Generative AI-Enhanced Data Engineering Pipelines for Predictive Biomarker Discovery in Alzheimer’s Disease and Kidney Disease: an objective, evidence-based, formal study of methodologies, architectures, and implications, with clear, parsimonious argumentation and rigorous evaluation.
Concise, objective synthesis of the study’s aims, hypotheses, scope, and contributions; specification of research questions; expected impact on biomarker discovery. The clinical significance of Alzheimer’s disease risk-modifying biomarkers is widely accepted. Nevertheless, despite pervasive data science activity in the search for predictive biomarkers, DNA-based predictors remain elusive, proteomic-based predictors are too often unreplicated, and AI-based predictors are often unvalidated and poorly understood. The soaring number of data repositories holds great potential for the discovery of predictive disease biomarkers; however, issues with data quality, integration, reproducibility, and lack of adequate engineering pipelines hinder this promise. Existing full data engineering pipelines are rarely employed. Generative AI is a novel, emerging area of research and application with potential to transform traditional information-technology and data-engineering infrastructure, with broad implications for data engineering for Alzheimer’s disease, kidney disease, and the search for other predictive disease biomarkers.
Generative AI is increasingly being used in the biomedical domain. Nevertheless, generative-AI-enhanced data-engineering pipelines that support the entire data-flow lifecycle of predictive biomarker discovery remain to be published. Questions include how generative AI can enhance pipelines, what data engineering contributions will be important to pipeline success, and how qualitative pipeline success will be achieved. The pipeline built-in for-preparation, data-acquisition, -curation, -integration, -preprocessing, -quality-control, and -metadata-standard definition is described, with special attention to balancing reproducibility, flexibility, and scalability. Development subcomponents include a state-of-the-art age-grouped biomarker list for healthy-adult-status monitoring and DNA-typical and predictive-biomarker-quality-validation-or-approach-type-typical models and approaches for data-harmonization quality control.
References
[1] Aisen, P. S., Sperling, R. A., Cummings, J., Jack, C. R., Morris, J. C., Sperling, R., & Donohue, M. C. (2023). The Alzheimer’s Disease Neuroimaging Initiative: Progress and future plans. Alzheimer’s & Dementia, 19(1), 3–15.
[2] Alipanahi, B., Delong, A., Weirauch, M. T., & Frey, B. J. (2015). Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning. Nature Biotechnology, 33(8), 831–838.
[3] Armañanzas, R., Ascoli, G. A., & McDonnell, M. D. (2021). Machine learning in neurodegenerative disease research. Briefings in Bioinformatics, 22(4), bbaa359.
[4] Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2020). Alzheimer’s disease. The Lancet, 395(10219), 101–117.
[5] Boehme, M., Huerta, J. M., Kacprowski, T., & Meyre, D. (2022). Multi-omics integration in biomedical research. Nature Reviews Genetics, 23(5), 321–337.
[6] Chen, R. J., Lu, M. Y., Wang, J., Williamson, D. F. K., & Mahmood, F. (2023). Pathomic fusion: An integrated framework for fusing histopathology and genomic features for cancer diagnosis. IEEE Transactions on Medical Imaging, 42(2), 757–770.
[7] Chen, T., Kornblith, S., Norouzi, M., & Hinton, G. (2020). A simple framework for contrastive learning of visual representations. Proceedings of the International Conference on Machine Learning, 1597–1607.
[8] DeBoever, C., Li, H., Jakubosky, D., Benaglio, P., Reyna, J., Olson, K. M., & Montgomery, S. B. (2018). Medical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study. Nature Communications, 9(1), 1612.
[9] Esteva, A., Robicquet, A., Ramsundar, B., Kuleshov, V., DePristo, M., Chou, K., & Dean, J. (2019). A guide to deep learning in healthcare. Nature Medicine, 25(1), 24–29.
[10] Fröhlich, H., Patjoshi, S., & Monti, S. (2023). Deep learning for multi-omics data integration in biomedical research. Bioinformatics, 39(1), btac769.
[11] Gottesman, O., Kuivaniemi, H., Tromp, G., Faucett, W. A., Li, R., Manolio, T. A., & eMERGE Network. (2013). The electronic medical records and genomics (eMERGE) network. Genetics in Medicine, 15(10), 761–771.
[12] Hampel, H., Vergallo, A., Perry, G., & Lista, S. (2021). The Alzheimer precision medicine initiative. Journal of Alzheimer’s Disease, 82(1), 1–21.
[13] Hu, Q., Greene, C. S., & Huan, T. (2022). Generative adversarial networks in biomedical informatics. Journal of Biomedical Informatics, 125, 103950.
[14] Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., & Sperling, R. A. (2018). NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562.
[15] Johnson, A. E. W., Pollard, T. J., Shen, L., Lehman, L. W. H., Feng, M., Ghassemi, M., & Mark, R. G. (2016). MIMIC-III, a freely accessible critical care database. Scientific Data, 3, 160035.
[16] Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., & Hassabis, D. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873), 583–589.
[17] Keshavan, A., Yeatman, J. D., & Rokem, A. (2020). Combining complementary imaging biomarkers for Alzheimer’s disease. NeuroImage, 216, 116876.
[18] Kundu, S., & Shetty, S. (2023). Explainable AI for clinical decision support: A survey. Artificial Intelligence in Medicine, 140, 102521.
[19] Libbrecht, M. W., & Noble, W. S. (2015). Machine learning applications in genetics and genomics. Nature Reviews Genetics, 16(6), 321–332.
[20] Lipton, Z. C. (2018). The mythos of model interpretability. Communications of the ACM, 61(10), 36–43.
[21] Lundberg, S. M., & Lee, S. I. (2017). A unified approach to interpreting model predictions. Advances in Neural Information Processing Systems, 30, 4765–4774.
[22] Monti, S., Tamayo, P., Mesirov, J., & Golub, T. (2003). Consensus clustering: A resampling-based method for class discovery. Machine Learning, 52(1), 91–118.
[23] O’Bryant, S. E., Gupta, V., Henriksen, K., Edwards, M., Jeromin, A., Lista, S., & Hampel, H. (2015). Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease. Alzheimer’s & Dementia, 11(5), 549–560.
[24] Paszke, A., Gross, S., Massa, F., Lerer, A., Bradbury, J., Chanan, G., & Chintala, S. (2019). PyTorch: An imperative style, high-performance deep learning library. Advances in Neural Information Processing Systems, 32, 8024–8035.
[25] Rajkomar, A., Dean, J., & Kohane, I. (2019). Machine learning in medicine. New England Journal of Medicine, 380(14), 1347–1358.
[26] Reeve, E., Trenaman, S. C., Rockwood, K., & Hilmer, S. N. (2017). Pharmacokinetic and pharmacodynamic changes in older adults. British Journal of Clinical Pharmacology, 83(1), 15–24.
[27] Saharia, C., Ho, J., Chan, W., Sohl-Dickstein, J., & Norouzi, M. (2022). Image super-resolution via iterative refinement. IEEE Transactions on Pattern Analysis and Machine Intelligence, 45(4), 4713–4729.
[28] Shen, D., Wu, G., & Suk, H. I. (2017). Deep learning in medical image analysis. Annual Review of Biomedical Engineering, 19, 221–248.
[29] Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., & Mesirov, J. P. (2005). Gene set enrichment analysis. Proceedings of the National Academy of Sciences, 102(43), 15545–15550.
[30] Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56.
[31] Van der Schaar, M., Alaa, A. M., Floto, A., Gimson, A., Scholtes, S., Wood, A., & McKinney, E. (2021). How artificial intelligence and machine learning can help healthcare systems respond to COVID-19. Machine Learning, 110(1), 1–14.
[32] Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., Appleton, G., Axton, M., Baak, A., & Mons, B. (2016). The FAIR guiding principles for scientific data management and stewardship. Scientific Data, 3, 160018.
[33] Zeng, P., & Zhou, X. (2019). Causal network inference in systems biology. Bioinformatics, 35(21), 4017–4024.
[34] Zhang, Z., Yang, H., & He, J. (2024). Generative models for multi-omics data integration in precision medicine. Briefings in Bioinformatics, 25(1), bbac614.
[35] Zhou, T., Shen, J., Yang, L., & Li, X. (2023). Machine learning-based biomarker discovery for chronic kidney disease progression.
Additional Files
Published
Data Availability Statement
The pipeline framework references publicly available datasets including the Alzheimer's Disease Neuroimaging Initiative (ADNI), OpenNeuro, TCGA, GTEx, dbGaP, MIMIC-III, and the European Genome-phenome Archive (EGA), all accessible through their respective portals.
